

## Zejula<sup>®</sup> (Niraparib) Prior Authorization Form

Member Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_ Member ID#: \_\_\_\_\_

### Drug Information

Pharmacy Billing (NDC: \_\_\_\_\_) Start Date (or date of next dose): \_\_\_\_\_

Dose: \_\_\_\_\_ Regimen: \_\_\_\_\_

### Pharmacy Information

Pharmacy NPI: \_\_\_\_\_ Pharmacy Name: \_\_\_\_\_

Pharmacy Phone: \_\_\_\_\_ Pharmacy Fax: \_\_\_\_\_

### Prescriber Information

Prescriber NPI: \_\_\_\_\_ Prescriber Name: \_\_\_\_\_

Prescriber Phone: \_\_\_\_\_ Prescriber Fax: \_\_\_\_\_ Specialty: \_\_\_\_\_

### Criteria

#### For Initial Authorization:

1. Please indicate the diagnosis and information:

Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Maintenance Treatment

A. Is the member's disease advanced or recurrent? Yes  No

B. Is disease in a complete or partial response to platinum chemotherapy? Yes  No

C. Is niraparib being used for maintenance following recurrence? Yes  No

i. If yes, is disease positive for a BRCA mutation? Yes  No

D. Will niraparib be used as a single-agent? Yes  No

If diagnosis is none of the above, please indicate diagnosis: \_\_\_\_\_

Additional Information: \_\_\_\_\_

#### For Continued Authorization:

1. Date of last dose: \_\_\_\_\_

2. Does member have any evidence of progressive disease while on niraparib? Yes  No

3. Has the member experienced adverse drug reactions related to niraparib therapy? Yes  No

If yes, please specify adverse reactions: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

**I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.**

*Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.*

Fax completed prior authorization request form to  
**888-601-8461** or submit Electronic Prior Authorization  
through CoverMyMeds<sup>®</sup> or SureScripts.

All requested data must be provided. Incomplete forms or  
forms without the chart notes will be returned. Pharmacy  
Coverage Guidelines are available at  
**AetnaBetterHealth.com/Oklahoma.**

#### CONFIDENTIALITY NOTICE

*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*